Education
About Us
Working with TipRanks
Follow Us
Inhibrx Biosciences Inc (INBX)
NASDAQ:INBX
INBX Stock Chart & Stats
$68.49
-$0.31(-2.00%)
At close: 4:00 PM EST
$68.49
-$0.31(-2.00%)
Day’s Range― - ―
52-Week Range$10.81 - $39.27
Previous CloseN/A
Volume23.61K
Average Volume (3M)142.18K
Market Cap
$553.63M
Enterprise Value$140.95M
Total Cash (Recent Filing)$186.57M
Total Debt (Recent Filing)$7.51M
Price to Earnings (P/E)0.2
Beta0.58
Next Earnings
Nov 13, 2025EPS Estimate
-1.72Last Dividend Ex-Date
May 30, 2024Dividend YieldN/A
Share Statistics
EPS (TTM)-1.85
Shares Outstanding14,485,421
10 Day Avg. Volume168,676
30 Day Avg. Volume142,179
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.67
Price to Sales (P/S)1114.64
P/FCF Ratio-1.13
Enterprise Value/Market Cap0.25
Enterprise Value/Revenue100.68
Enterprise Value/Gross Profit-101.62
Enterprise Value/Ebitda-0.89
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering0
Bulls Say, Bears Say
Bulls Say
Efficacy Of TreatmentOzekibart FOLFIRI combo shows 40% ORR, demonstrating effectiveness in heavily pretreated CRC patients.
Financial StabilityInhibrx is well capitalized with $196.3 million in cash, allowing continued development of its key treatments.
Bears Say
Adverse Effects31% of patients experienced an increase in alanine aminotransferase, indicating potential safety issues.
Safety ConcernsA patient passed away due to neutropenic sepsis, raising concerns about the safety profile of the treatment.
Inhibrx Biosciences Inc News
INBX FAQ
What was Inhibrx Biosciences Inc’s price range in the past 12 months?
Inhibrx Biosciences Inc lowest stock price was $10.80 and its highest was $39.27 in the past 12 months.
What is Inhibrx Biosciences Inc’s market cap?
Inhibrx Biosciences Inc’s market cap is $553.63M.
When is Inhibrx Biosciences Inc’s upcoming earnings report date?
Inhibrx Biosciences Inc’s upcoming earnings report date is Nov 13, 2025 which is in 14 days.
How were Inhibrx Biosciences Inc’s earnings last quarter?
Inhibrx Biosciences Inc released its earnings results on Aug 13, 2025. The company reported -$1.85 earnings per share for the quarter, beating the consensus estimate of -$2.76 by $0.91.
Is Inhibrx Biosciences Inc overvalued?
According to Wall Street analysts Inhibrx Biosciences Inc’s price is currently Overvalued.
Does Inhibrx Biosciences Inc pay dividends?
Inhibrx Biosciences Inc pays a Notavailable dividend of $0.85 which represents an annual dividend yield of N/A. See more information on Inhibrx Biosciences Inc dividends here
What is Inhibrx Biosciences Inc’s EPS estimate?
Inhibrx Biosciences Inc’s EPS estimate is -1.72.
How many shares outstanding does Inhibrx Biosciences Inc have?
Inhibrx Biosciences Inc has 14,485,421 shares outstanding.
What happened to Inhibrx Biosciences Inc’s price movement after its last earnings report?
Inhibrx Biosciences Inc reported an EPS of -$1.85 in its last earnings report, beating expectations of -$2.76. Following the earnings report the stock price went up 7.527%.
Which hedge fund is a major shareholder of Inhibrx Biosciences Inc?
Currently, no hedge funds are holding shares in INBX
Inhibrx Biosciences Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
― (―)
― (―)
Hedge Fund Trend
Increased
By 218.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $11.3M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
130.36%
12-Months-Change
Fundamentals
Return on Equity
-113.71%
Trailing 12-Months
Asset Growth
-17.92%
Trailing 12-Months
Company Description
Inhibrx Biosciences Inc
Inhibrx Biosciences Inc (INBX) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer and other serious diseases. The company specializes in the design and development of a new class of antibody-drug conjugates and bispecific antibodies that aim to improve treatment outcomes for patients with high unmet medical needs. Inhibrx's core products include its proprietary therapeutic candidates which are in various stages of clinical trials targeting specific cancer indications.
Technical Analysis
Prothena
―
CytomX Therapeutics
―
Humacyte
―
Monte Rosa Therapeutics
―
Candel Therapeutics
―
Ownership Overview
9.78% Insiders
6.34% Mutual Funds
45.87% Other Institutional Investors
31.01% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---